Half-year report · HY
177A.TEDINET S100X2IH
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥258m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥380m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥272m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥417m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥274m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥367m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥795m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.3bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥916m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥518m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥467m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥220m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.53 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥157.57 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.7 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 65.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥283m |
| Cell Process Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥76m |
| Microbiological Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥36m |
| Tissue Culture Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥501m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥541m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥265m |
| Cell Process Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥191m |
| Microbiological Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥104m |
| Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥350m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥645m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | 1281800000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | 686263000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | 536415000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 2504480000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 2504480000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | 1281800000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | 686263000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | 536415000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 2504480000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | InterimDuration | 2504480000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | 501303000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | -36186000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | 75576000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 540693000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | -283040000 | JPY |
| Operating income | InterimDuration | 257653000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-13 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第45期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)コージンバイオ株式会社 | |
| Company name in english cover page | FilingDateInstant | Kohjin Bio Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 中村 孝人 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)埼玉県坂戸市千代田五丁目１番地３ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)049-284-3781（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務執行役員 平田 賢二 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都豊島区西池袋一丁目11番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5784-2272 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務執行役員 平田 賢二 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E38689 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 177A0 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)コージンバイオ株式会社 | |
| Filer name in english | FilingDateInstant | Kohjin Bio Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |